<DOC>
	<DOCNO>NCT00391950</DOCNO>
	<brief_summary>The purpose study see give zoledronic acid three time year effective five time year , increase bone strength men prostate cancer . All participant receive active drug half receive drug every 6 month half receive drug every 3 month . Both patient doctor know treatment patient receiving . After 1 year treatment bone strength measure scan compare strength start study . All participant stop receive drug 1 year see back clinic , annually another 2 year follow-up .</brief_summary>
	<brief_title>Maintaining Bone Strength Men With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis carcinoma prostate No distant metastases Patients must candidate androgen deprivation therapy ( ADT ) Patient baseline BMD Tscore 1 standard deviation lumbar spine ( L2L4 ) eligible Exclusion criterion : Patients normal BMD trial entry Patients receive prior bisphosphonate therapy past 12 month Treatment antiandrogen mono combination therapy Patients currently receive diethylstilbesterol ( DES ) previously receive PCSPES Patients receive prior treatment systemic corticosteroid within past 12 month Patients prior exposure anabolic steroid growth hormone within past 6 month Patients prior treatment osteoporosis Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Cancer treatment induce bone loss ( CTIBL )</keyword>
	<keyword>Androgen deprivation therapy ( ADT )</keyword>
</DOC>